Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
Authors:
- Stephen B HanauerSHStephen B Hanauer
- Gary L GitnickGGGary L Gitnick
- Mark A PeppercornMPMark A Peppercorn
- Malcolm G RobinsonMRMalcolm G Robinson
- Lawrence D WrubleLWLawrence D Wruble
- Edward L KrawittEKEdward L Krawitt
- 1 May 1993
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 104 (5) , 1293-1301
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Slow-Release 5-Amino-Salicylic Acid (Pentasa®) for the Treatment of Active Crohn’s DiseaseDigestion, 1990
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- 5-Aminosalicylic Acid in the Treatment of Crohn's Disease: A 16-Week Double-Blind, Placebo-Controlled, Multicentre Study with Pentasa®Scandinavian Journal of Gastroenterology, 1987
- Effect of a Slow-Release 5´-Aminosalicylic Acid Preparation on Disease Activity in Crohn’s DiseaseDigestion, 1986
- SulfasalazineAnnals of Internal Medicine, 1984
- Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study.Gut, 1981
- Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's DiseaseNew England Journal of Medicine, 1980
- Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.Gut, 1980
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977